Invanz Sandbox: Difference between revisions

Invanz is used to treat a range of bacterial infections caused by Gram positive and Gram negative bacteria as well as a range of both aerobic and anaerobic bacteria. Invanz works by inhibiting cell wall synthesis via binding to penicillin binding proteins (PBPs). Invanz is stable against hydrolysis from many beta-lactamases including penicillinases and cephalosporinases, but is unstable against metallo-beta-lactamases <ref name="merck" />. Beta-lactamases are secreted by bacteria to provide resistance to antibiotics; however, Invanz is relatively unaffected by these beta-lactamases and thus is an effective treatment for various bacterial infections <ref>PMID: 25561890</ref>. Beta-lactamases work by attacking and cleaving the beta-lactam ring of antibiotics before the antibiotic reaches its target such as the penicilling binding proteins <ref>PMID: 4303295</ref>. The unique structural features of Invanz equip this drug with some of the widest spectrum and most potent antimicrobial activity of carbapenem antibiotics today <ref>PMID: 12951340</ref>.